Alexander M. Menzies,Serigne Lo,Robyn P.M. Saw,Maria Gonzalez,Sydney Ch’ng,O E Nieweg,Kerwin F. Shannon,P M Ferguson,Jenny Lee,Louise Emmett,R Kapoor,R V Rawson,Jonathan R. Stretch,John F. Thompson,A J Spillane,Helen Rizos,R A Scolyer,Georgina V. Long
Neoadjuvant dabrafenib plus trametinib has a high pathological response rate and impressive short-term survival in patients with resectable stage III melanoma. We report 5-year outcomes from the phase II NeoCombi trial.